Antidepressant Drugs Market by Product (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors, and Others), Depressive Dis

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,125	215 Pages	Allied Market Research	February, 2022	ALMR17117572

Best Price Guarantee
Price	from $4,125
Length	215 Pages
Publisher	Allied Market Research
Published Date	February, 2022
SKU	ALMR17117572

Antidepressant Drugs Market by Product (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors, and Others), Depressive Disorder (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others): Global Opportunity Analysis and Industry Forecast, 2021–2030

The global antidepressant drugs market was valued at $15,651.0 million in 2020, and is projected to reach $ 21,004.8 million by 2030, registering a CAGR of 3.0 % from 2021 to 2030.

Depression includes a variety of mental health problems characterized by absence of positive emotion, low mood, and a range of associated cognitive, physical, emotional, and behavioral symptoms. It is a very common condition that affects 1 in every 5 Americans. There are many factors such as genetic factors, stress and brain chemistry, which leads to depression.

Increase in prevalence of depression, rise in geriatric population, and advancements in R&D activities in the pharmaceutical industry to develop innovative drugs drive the market. Moreover, increase in awareness regarding depression, increase in number of clinical trials, and rise in number of populations suffering from stress fuel growth of the antidepressant drugs market. In addition, rise in number of geriatric population drive growth of the market. This is attributed to the fact that geriatric population is highly vulnerable to depression diseases, owing to social isolation and loneliness, which boosts demand for various antidepressant drug therapies for better health outcomes. According to the Journal of The National Academic of Science, in 2020, it was reported that around one-third of adults above the age of 65 years fell lonely and one fourth of adults above 65 years are socially isolated. In addition, according to the Journal of National Institute on Aging, in February 2022, it was reported that loneliness and social isolation are associated with higher rate of depression.

The key factors that drive growth of the market include increased depression and stress levels as in young generation as well as in older people are more prone to diseases including subsyndromal depression and other stress-related disorders. Other factors such as chronic medical conditions, crimes such as sexual abuse, femicide along other behavioral issues further lead to depression, which, in turn, creates demand for antidepressant drugs. However, lack of availability, awareness in undeveloped economies, along with patent expiration of drugs restrain the market growth.

However, poor efficacy and safety profiles of drugs, preference for non-pharmacological therapies, and increase in number of patent expiration of antidepressants that lead to weak pipeline are expected to hamper the market growth.

The global antidepressant drugs market is segmented on the basis of product, depressive disorder, and region. By product, the market is categorized into tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, serotonin antagonist & reuptake inhibitors, and others.

On the basis of depressive disorder, it is divided into major depressive disorder, obsessive-compulsive disorder, generalized anxiety disorder, panic disorder, and others.

Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Some of the major companies that operate in the global antidepressant drugs market are Alkermes Plc, AbbVie Inc., Eli Lilly And Company, GlaxoSmithKline, Inc., H. Lundbeck A/S, Merck KGAA, Pfizer Inc., Teva Pharmaceutical Industries Ltd. (Actavis Generics), and Takeda Pharmaceutical Limited Company.

KEY BENEFITS FOR STAKEHOLDERS

The report provides an in-depth analysis of the global antidepressant drugs market size along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global antidepressant drugs market.

KEY MARKET SEGMENTS

By Product

Tricyclic Antidepressants
Selective Serotonin Reuptake Inhibitors
Serotonin Norepinephrine Reuptake Inhibitors
Monoamine Oxidase Inhibitors
Serotonin Antagonist and Reuptake Inhibitors
Others

By Depressive Disorder

Major Depressive Disorder
Obsessive-Compulsive Disorder
Generalized Anxiety Disorder
Panic Disorder
Others

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

KEY MARKET PLAYERS

Alkermes Plc
AbbVie Inc.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline, Inc.
H. Lundbeck A/S
Merck KGAA
Pfizer Inc.
Teva Pharmaceutical Industries Ltd. (Actavis Generics)
Takeda Pharmaceutical Limited Company

CHAPTER 1:INTRODUCTION: 1.1.Report Description; 1.2.Key Market Segments; 1.3.Key Benefits; 1.4.Research Methodology; 1.4.1. Primary Research; 1.4.2. Secondary Research; 1.4.3. Analyst Tools and Models
CHAPTER 2:EXECUTIVE SUMMARY: 2.1.CXO Perspective
CHAPTER 3:MARKET LANDSCAPE: 3.1.Market Definition and Scope; 3.2.Key Findings; 3.2.1. Top Investment Pockets; 3.2.2. Top Winning Strategies; 3.3.Porter's Five Forces Analysis; 3.3.1. Bargaining Power of Suppliers; 3.3.2. Threat of New Entrants; 3.3.3. Threat of Substitutes; 3.3.4. Competitive Rivalry; 3.3.5. Bargaining Power among Buyers; 3.4.Market Share Analysis/Top Player Positioning; 3.4.1. Market Share Analysis/Top Player Positioning 2020; 3.5.Market Dynamics; 3.5.1. Drivers; 3.5.2. Restraints; 3.5.3. Opportunities; 3.6. COVID-19 Impact Analysis
CHAPTER 4:ANTIDEPRESSANT DRUGS MARKET, BY DEPRESSIVE DISORDER: 4.1.Market Overview; 4.1.1Market Size and Forecast, By Depressive Disorder; 4.2. Major Depressive Disorder; 4.2.1. Key Market Trends, Growth Factors and Opportunities; 4.2.2. Market Size and Forecast, By Region; 4.2.3. Market Share Analysis, By Country; 4.3. Obsessive Compulsive Disorder; 4.3.1. Key Market Trends, Growth Factors and Opportunities; 4.3.2. Market Size and Forecast, By Region; 4.3.3. Market Share Analysis, By Country; 4.4. Generalized Anxiety Disorder; 4.4.1. Key Market Trends, Growth Factors and Opportunities; 4.4.2. Market Size and Forecast, By Region; 4.4.3. Market Share Analysis, By Country; 4.5. Panic Disorder; 4.5.1. Key Market Trends, Growth Factors and Opportunities; 4.5.2. Market Size and Forecast, By Region; 4.5.3. Market Share Analysis, By Country; 4.6. Others; 4.6.1. Key Market Trends, Growth Factors and Opportunities; 4.6.2. Market Size and Forecast, By Region; 4.6.3. Market Share Analysis, By Country
CHAPTER 5:ANTIDEPRESSANT DRUGS MARKET, BY PRODUCT: 5.1.Market Overview; 5.1.1Market Size and Forecast, By Product; 5.2. Selective Serotonin Reuptake Inhibitors; 5.2.1. Key Market Trends, Growth Factors and Opportunities; 5.2.2. Market Size and Forecast, By Region; 5.2.3. Market Share Analysis, By Country; 5.3. Serotonin Norepinephrine Reuptake Inhibitors; 5.3.1. Key Market Trends, Growth Factors and Opportunities; 5.3.2. Market Size and Forecast, By Region; 5.3.3. Market Share Analysis, By Country; 5.4. Monoamine Oxidase Inhibitors; 5.4.1. Key Market Trends, Growth Factors and Opportunities; 5.4.2. Market Size and Forecast, By Region; 5.4.3. Market Share Analysis, By Country; 5.5. Serotonin Antagonist and Reuptake Inhibitors; 5.5.1. Key Market Trends, Growth Factors and Opportunities; 5.5.2. Market Size and Forecast, By Region; 5.5.3. Market Share Analysis, By Country; 5.6. Others; 5.6.1. Key Market Trends, Growth Factors and Opportunities; 5.6.2. Market Size and Forecast, By Region; 5.6.3. Market Share Analysis, By Country; 5.7. Tricyclic Antidepressants; 5.7.1. Key Market Trends, Growth Factors and Opportunities; 5.7.2. Market Size and Forecast, By Region; 5.7.3. Market Share Analysis, By Country
CHAPTER 6:ANTIDEPRESSANT DRUGS MARKET, BY REGION: 6.1.Market Overview; 6.1.1Market Size and Forecast, By Region; 6.2.Asia-Pacific; 6.2.1. Key Market Trends and Opportunities; 6.2.2. Market Size and Forecast, By Depressive Disorder; 6.2.3. Market Size and Forecast, By Product; 6.2.4. Market Size and Forecast, By Country; 6.2.5. China Antidepressant Drugs Market; 6.2.5.1. Market Size and Forecast, By Depressive Disorder; 6.2.5.2. Market Size and Forecast, By Product; 6.2.6. Japan Antidepressant Drugs Market; 6.2.6.1. Market Size and Forecast, By Depressive Disorder; 6.2.6.2. Market Size and Forecast, By Product; 6.2.7. India Antidepressant Drugs Market; 6.2.7.1. Market Size and Forecast, By Depressive Disorder; 6.2.7.2. Market Size and Forecast, By Product; 6.2.8. South Korea Antidepressant Drugs Market; 6.2.8.1. Market Size and Forecast, By Depressive Disorder; 6.2.8.2. Market Size and Forecast, By Product; 6.2.9. Australia Antidepressant Drugs Market; 6.2.9.1. Market Size and Forecast, By Depressive Disorder; 6.2.9.2. Market Size and Forecast, By Product; 6.2.10. Rest of Asia Pacific Antidepressant Drugs Market; 6.2.10.1. Market Size and Forecast, By Depressive Disorder; 6.2.10.2. Market Size and Forecast, By Product; 6.3.LAMEA; 6.3.1. Key Market Trends and Opportunities; 6.3.2. Market Size and Forecast, By Depressive Disorder; 6.3.3. Market Size and Forecast, By Product; 6.3.4. Market Size and Forecast, By Country; 6.3.5. Brazil Antidepressant Drugs Market; 6.3.5.1. Market Size and Forecast, By Depressive Disorder; 6.3.5.2. Market Size and Forecast, By Product; 6.3.6. South Africa, Antidepressant Drugs Market; 6.3.6.1. Market Size and Forecast, By Depressive Disorder; 6.3.6.2. Market Size and Forecast, By Product; 6.3.7. Saudi Arabia Antidepressant Drugs Market; 6.3.7.1. Market Size and Forecast, By Depressive Disorder; 6.3.7.2. Market Size and Forecast, By Product; 6.3.8. Rest of LAMEA Antidepressant Drugs Market; 6.3.8.1. Market Size and Forecast, By Depressive Disorder; 6.3.8.2. Market Size and Forecast, By Product; 6.4.North America; 6.4.1. Key Market Trends and Opportunities; 6.4.2. Market Size and Forecast, By Depressive Disorder; 6.4.3. Market Size and Forecast, By Product; 6.4.4. Market Size and Forecast, By Country; 6.4.5. United States Antidepressant Drugs Market; 6.4.5.1. Market Size and Forecast, By Depressive Disorder; 6.4.5.2. Market Size and Forecast, By Product; 6.4.6. Canada Antidepressant Drugs Market; 6.4.6.1. Market Size and Forecast, By Depressive Disorder; 6.4.6.2. Market Size and Forecast, By Product; 6.4.7. Mexico Antidepressant Drugs Market; 6.4.7.1. Market Size and Forecast, By Depressive Disorder; 6.4.7.2. Market Size and Forecast, By Product; 6.5.Europe; 6.5.1. Key Market Trends and Opportunities; 6.5.2. Market Size and Forecast, By Depressive Disorder; 6.5.3. Market Size and Forecast, By Product; 6.5.4. Market Size and Forecast, By Country; 6.5.5. Germany Antidepressant Drugs Market; 6.5.5.1. Market Size and Forecast, By Depressive Disorder; 6.5.5.2. Market Size and Forecast, By Product; 6.5.6. France Antidepressant Drugs Market; 6.5.6.1. Market Size and Forecast, By Depressive Disorder; 6.5.6.2. Market Size and Forecast, By Product; 6.5.7. U.K Antidepressant Drugs Market; 6.5.7.1. Market Size and Forecast, By Depressive Disorder; 6.5.7.2. Market Size and Forecast, By Product; 6.5.8. Italy Antidepressant Drugs Market; 6.5.8.1. Market Size and Forecast, By Depressive Disorder; 6.5.8.2. Market Size and Forecast, By Product; 6.5.9. Spain Antidepressant Drugs Market; 6.5.9.1. Market Size and Forecast, By Depressive Disorder; 6.5.9.2. Market Size and Forecast, By Product; 6.5.10. Rest of Europe Antidepressant Drugs Market; 6.5.10.1. Market Size and Forecast, By Depressive Disorder; 6.5.10.2. Market Size and Forecast, By Product
CHAPTER 7:COMPANY PROFILES: 7.1. Alkermes Plc.; 7.1.1.Company Overview; 7.1.2.Key Executives; 7.1.3.Company snapshot; 7.1.4.Operating business segments; 7.1.5.Product portfolio; 7.1.6.Business Performance; 7.1.7.Key Strategic Moves and Developments; 7.2. AbbVie Inc.; 7.2.1.Company Overview; 7.2.2.Key Executives; 7.2.3.Company snapshot; 7.2.4.Operating business segments; 7.2.5.Product portfolio; 7.2.6.Business Performance; 7.2.7.Key Strategic Moves and Developments; 7.3. Eli Lilly and Company; 7.3.1.Company Overview; 7.3.2.Key Executives; 7.3.3.Company snapshot; 7.3.4.Operating business segments; 7.3.5.Product portfolio; 7.3.6.Business Performance; 7.3.7.Key Strategic Moves and Developments; 7.4. GlaxoSmithKline, Inc.; 7.4.1.Company Overview; 7.4.2.Key Executives; 7.4.3.Company snapshot; 7.4.4.Operating business segments; 7.4.5.Product portfolio; 7.4.6.Business Performance; 7.4.7.Key Strategic Moves and Developments; 7.5. H. Lundbeck A S; 7.5.1.Company Overview; 7.5.2.Key Executives; 7.5.3.Company snapshot; 7.5.4.Operating business segments; 7.5.5.Product portfolio; 7.5.6.Business Performance; 7.5.7.Key Strategic Moves and Developments; 7.6. F. Hoffmann-La Roche Ltd; 7.6.1.Company Overview; 7.6.2.Key Executives; 7.6.3.Company snapshot; 7.6.4.Operating business segments; 7.6.5.Product portfolio; 7.6.6.Business Performance; 7.6.7.Key Strategic Moves and Developments; 7.7. Merck KGAA; 7.7.1.Company Overview; 7.7.2.Key Executives; 7.7.3.Company snapshot; 7.7.4.Operating business segments; 7.7.5.Product portfolio; 7.7.6.Business Performance; 7.7.7.Key Strategic Moves and Developments; 7.8. Pfizer Inc.; 7.8.1.Company Overview; 7.8.2.Key Executives; 7.8.3.Company snapshot; 7.8.4.Operating business segments; 7.8.5.Product portfolio; 7.8.6.Business Performance; 7.8.7.Key Strategic Moves and Developments; 7.9. Teva Pharmaceutical Industries Ltd; 7.9.1.Company Overview; 7.9.2.Key Executives; 7.9.3.Company snapshot; 7.9.4.Operating business segments; 7.9.5.Product portfolio; 7.9.6.Business Performance; 7.9.7.Key Strategic Moves and Developments; 7.10. Takeda Pharmaceutical Limited Company; 7.10.1.Company Overview; 7.10.2.Key Executives; 7.10.3.Company snapshot; 7.10.4.Operating business segments; 7.10.5.Product portfolio; 7.10.6.Business Performance; 7.10.7.Key Strategic Moves and Developments
LIST OF TABLES: TABLE 1.GLOBAL ANTIDEPRESSANT DRUGS MARKET, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION); TABLE 2.GLOBAL ANTIDEPRESSANT DRUGS MARKET FOR MAJOR DEPRESSIVE DISORDER, BY REGION, 2020-2030 ($MILLION); TABLE 3.GLOBAL ANTIDEPRESSANT DRUGS MARKET FOR OBSESSIVE COMPULSIVE DISORDER, BY REGION, 2020-2030 ($MILLION); TABLE 4.GLOBAL ANTIDEPRESSANT DRUGS MARKET FOR GENERALIZED ANXIETY DISORDER, BY REGION, 2020-2030 ($MILLION); TABLE 5.GLOBAL ANTIDEPRESSANT DRUGS MARKET FOR PANIC DISORDER, BY REGION, 2020-2030 ($MILLION); TABLE 6.GLOBAL ANTIDEPRESSANT DRUGS MARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION); TABLE 7.GLOBAL ANTIDEPRESSANT DRUGS MARKET, BY PRODUCT, 2020-2030 ($MILLION); TABLE 8.GLOBAL ANTIDEPRESSANT DRUGS MARKET FOR SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2020-2030 ($MILLION); TABLE 9.GLOBAL ANTIDEPRESSANT DRUGS MARKET FOR SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, BY REGION, 2020-2030 ($MILLION); TABLE 10.GLOBAL ANTIDEPRESSANT DRUGS MARKET FOR MONOAMINE OXIDASE INHIBITORS, BY REGION, 2020-2030 ($MILLION); TABLE 11.GLOBAL ANTIDEPRESSANT DRUGS MARKET FOR SEROTONIN ANTAGONIST AND REUPTAKE INHIBITORS, BY REGION, 2020-2030 ($MILLION); TABLE 12.GLOBAL ANTIDEPRESSANT DRUGS MARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION); TABLE 13.GLOBAL ANTIDEPRESSANT DRUGS MARKET FOR TRICYCLIC ANTIDEPRESSANTS, BY REGION, 2020-2030 ($MILLION); TABLE 14.GLOBAL ANTIDEPRESSANT DRUGS MARKET, BY REGION, 2020-2030 ($MILLION); TABLE 15.ASIA-PACIFIC ANTIDEPRESSANT DRUGS, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION); TABLE 16.ASIA-PACIFIC ANTIDEPRESSANT DRUGS, BY PRODUCT, 2020-2030 ($MILLION); TABLE 17.CHINA ANTIDEPRESSANT DRUGS, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION); TABLE 18.CHINA ANTIDEPRESSANT DRUGS, BY PRODUCT, 2020-2030 ($MILLION); TABLE 19.JAPAN ANTIDEPRESSANT DRUGS, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION); TABLE 20.JAPAN ANTIDEPRESSANT DRUGS, BY PRODUCT, 2020-2030 ($MILLION); TABLE 21.INDIA ANTIDEPRESSANT DRUGS, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION); TABLE 22.INDIA ANTIDEPRESSANT DRUGS, BY PRODUCT, 2020-2030 ($MILLION); TABLE 23.SOUTH KOREA ANTIDEPRESSANT DRUGS, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION); TABLE 24.SOUTH KOREA ANTIDEPRESSANT DRUGS, BY PRODUCT, 2020-2030 ($MILLION); TABLE 25.AUSTRALIA ANTIDEPRESSANT DRUGS, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION); TABLE 26.AUSTRALIA ANTIDEPRESSANT DRUGS, BY PRODUCT, 2020-2030 ($MILLION); TABLE 27.REST OF ASIA PACIFIC ANTIDEPRESSANT DRUGS, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION); TABLE 28.REST OF ASIA PACIFIC ANTIDEPRESSANT DRUGS, BY PRODUCT, 2020-2030 ($MILLION); TABLE 29.LAMEA ANTIDEPRESSANT DRUGS, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION); TABLE 30.LAMEA ANTIDEPRESSANT DRUGS, BY PRODUCT, 2020-2030 ($MILLION); TABLE 31.BRAZIL ANTIDEPRESSANT DRUGS, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION); TABLE 32.BRAZIL ANTIDEPRESSANT DRUGS, BY PRODUCT, 2020-2030 ($MILLION); TABLE 33.SOUTH AFRICA, ANTIDEPRESSANT DRUGS, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION); TABLE 34.SOUTH AFRICA, ANTIDEPRESSANT DRUGS, BY PRODUCT, 2020-2030 ($MILLION); TABLE 35.SAUDI ARABIA ANTIDEPRESSANT DRUGS, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION); TABLE 36.SAUDI ARABIA ANTIDEPRESSANT DRUGS, BY PRODUCT, 2020-2030 ($MILLION); TABLE 37.REST OF LAMEA ANTIDEPRESSANT DRUGS, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION); TABLE 38.REST OF LAMEA ANTIDEPRESSANT DRUGS, BY PRODUCT, 2020-2030 ($MILLION); TABLE 39.NORTH AMERICA ANTIDEPRESSANT DRUGS, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION); TABLE 40.NORTH AMERICA ANTIDEPRESSANT DRUGS, BY PRODUCT, 2020-2030 ($MILLION); TABLE 41.UNITED STATES ANTIDEPRESSANT DRUGS, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION); TABLE 42.UNITED STATES ANTIDEPRESSANT DRUGS, BY PRODUCT, 2020-2030 ($MILLION); TABLE 43.CANADA ANTIDEPRESSANT DRUGS, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION); TABLE 44.CANADA ANTIDEPRESSANT DRUGS, BY PRODUCT, 2020-2030 ($MILLION); TABLE 45.MEXICO ANTIDEPRESSANT DRUGS, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION); TABLE 46.MEXICO ANTIDEPRESSANT DRUGS, BY PRODUCT, 2020-2030 ($MILLION); TABLE 47.EUROPE ANTIDEPRESSANT DRUGS, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION); TABLE 48.EUROPE ANTIDEPRESSANT DRUGS, BY PRODUCT, 2020-2030 ($MILLION); TABLE 49.GERMANY ANTIDEPRESSANT DRUGS, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION); TABLE 50.GERMANY ANTIDEPRESSANT DRUGS, BY PRODUCT, 2020-2030 ($MILLION); TABLE 51.FRANCE ANTIDEPRESSANT DRUGS, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION); TABLE 52.FRANCE ANTIDEPRESSANT DRUGS, BY PRODUCT, 2020-2030 ($MILLION); TABLE 53.UNITED KINGDOM ANTIDEPRESSANT DRUGS, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION); TABLE 54.UNITED KINGDOM ANTIDEPRESSANT DRUGS, BY PRODUCT, 2020-2030 ($MILLION); TABLE 55.ITALY ANTIDEPRESSANT DRUGS, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION); TABLE 56.ITALY ANTIDEPRESSANT DRUGS, BY PRODUCT, 2020-2030 ($MILLION); TABLE 57.SPAIN ANTIDEPRESSANT DRUGS, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION); TABLE 58.SPAIN ANTIDEPRESSANT DRUGS, BY PRODUCT, 2020-2030 ($MILLION); TABLE 59.REST OF EUROPE ANTIDEPRESSANT DRUGS, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION); TABLE 60.REST OF EUROPE ANTIDEPRESSANT DRUGS, BY PRODUCT, 2020-2030 ($MILLION); TABLE 61.ALKERMES PLC: KEY EXECUTIVES; TABLE 62.ALKERMES PLC: COMPANY SNAPSHOT; TABLE 63.ALKERMES PLC: OPERATING SEGMENTS; TABLE 64.ALKERMES PLC: PRODUCT PORTFOLIO; TABLE 65.ALKERMES PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 66.ABBVIE INC.: KEY EXECUTIVES; TABLE 67.ABBVIE INC.: COMPANY SNAPSHOT; TABLE 68.ABBVIE INC.: OPERATING SEGMENTS; TABLE 69.ABBVIE INC.: PRODUCT PORTFOLIO; TABLE 70.ABBVIE INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 71.ELI LILLY AND COMPANY: KEY EXECUTIVES; TABLE 72.ELI LILLY AND COMPANY: COMPANY SNAPSHOT; TABLE 73.ELI LILLY AND COMPANY: OPERATING SEGMENTS; TABLE 74.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO; TABLE 75.ELI LILLY AND COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 76.GLAXOSMITHKLINE, INC: KEY EXECUTIVES; TABLE 77.GLAXOSMITHKLINE, INC: COMPANY SNAPSHOT; TABLE 78.GLAXOSMITHKLINE, INC: OPERATING SEGMENTS; TABLE 79.GLAXOSMITHKLINE, INC: PRODUCT PORTFOLIO; TABLE 80.GLAXOSMITHKLINE, INC: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 81.H. LUNDBECK A S: KEY EXECUTIVES; TABLE 82.H. LUNDBECK A S: COMPANY SNAPSHOT; TABLE 83.H. LUNDBECK A S: OPERATING SEGMENTS; TABLE 84.H. LUNDBECK A S: PRODUCT PORTFOLIO; TABLE 85.H. LUNDBECK A S: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 86.F. HOFFMANN-LA ROCHE LTD: KEY EXECUTIVES; TABLE 87.F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT; TABLE 88.F. HOFFMANN-LA ROCHE LTD: OPERATING SEGMENTS; TABLE 89.F. HOFFMANN-LA ROCHE LTD: PRODUCT PORTFOLIO; TABLE 90.F. HOFFMANN-LA ROCHE LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 91.MERCK KGAA: KEY EXECUTIVES; TABLE 92.MERCK KGAA: COMPANY SNAPSHOT; TABLE 93.MERCK KGAA: OPERATING SEGMENTS; TABLE 94.MERCK KGAA: PRODUCT PORTFOLIO; TABLE 95.MERCK KGAA: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 96.PFIZER INC: KEY EXECUTIVES; TABLE 97.PFIZER INC: COMPANY SNAPSHOT; TABLE 98.PFIZER INC: OPERATING SEGMENTS; TABLE 99.PFIZER INC: PRODUCT PORTFOLIO; TABLE 100.PFIZER INC: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 101.TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY EXECUTIVES; TABLE 102.TEVA PHARMACEUTICAL INDUSTRIES LTD: COMPANY SNAPSHOT; TABLE 103.TEVA PHARMACEUTICAL INDUSTRIES LTD: OPERATING SEGMENTS; TABLE 104.TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT PORTFOLIO; TABLE 105.TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 106.TAKEDA PHARMACEUTICAL LIMITED COMPANY: KEY EXECUTIVES; TABLE 107.TAKEDA PHARMACEUTICAL LIMITED COMPANY: COMPANY SNAPSHOT; TABLE 108.TAKEDA PHARMACEUTICAL LIMITED COMPANY: OPERATING SEGMENTS; TABLE 109.TAKEDA PHARMACEUTICAL LIMITED COMPANY: PRODUCT PORTFOLIO; TABLE 110.TAKEDA PHARMACEUTICAL LIMITED COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES: FIGURE 1.GLOBAL ANTIDEPRESSANT DRUGS MARKET SEGMENTATION; FIGURE 2.GLOBAL ANTIDEPRESSANT DRUGS MARKET; FIGURE 3.SEGMENTATION ANTIDEPRESSANT DRUGS MARKET; FIGURE 4.TOP INVESTMENT POCKET IN ANTIDEPRESSANT DRUGS MARKET; FIGURE 5.TOP WINNING STRATEGIES, 2019-2021*; FIGURE 6.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019-2021(%); FIGURE 7.TOP WINNING STRATEGIES, BY COMPANY, 2019-2021*; FIGURE 8.MODERATE BARGAINING POWER OF BUYERS; FIGURE 9.MODERATE BARGAINING POWER OF SUPPLIERS; FIGURE 10.MODERATE THREAT OF NEW ENTRANTS; FIGURE 11.LOW THREAT OF SUBSTITUTION; FIGURE 12.HIGH COMPETITIVE RIVALRY; FIGURE 13.TOP PLAYER POSITIONING, 2020; FIGURE 14.MARKET SHARE ANALYSIS, 2020; FIGURE 15.RESTRAINTS AND DRIVERS: ANTIDEPRESSANT DRUGS MARKET; FIGURE 16.ANTIDEPRESSANT DRUGS MARKET SEGMENTATION, BY DEPRESSIVE DISORDER; FIGURE 17.ANTIDEPRESSANT DRUGS MARKET FOR MAJOR DEPRESSIVE DISORDER, BY COUNTRY, 2020-2030 ($MILLION); FIGURE 18.ANTIDEPRESSANT DRUGS MARKET FOR OBSESSIVE COMPULSIVE DISORDER, BY COUNTRY, 2020-2030 ($MILLION); FIGURE 19.ANTIDEPRESSANT DRUGS MARKET FOR GENERALIZED ANXIETY DISORDER, BY COUNTRY, 2020-2030 ($MILLION); FIGURE 20.ANTIDEPRESSANT DRUGS MARKET FOR PANIC DISORDER, BY COUNTRY, 2020-2030 ($MILLION); FIGURE 21.ANTIDEPRESSANT DRUGS MARKET FOR OTHERS, BY COUNTRY, 2020-2030 ($MILLION); FIGURE 22.ANTIDEPRESSANT DRUGS MARKET SEGMENTATION, BY PRODUCT; FIGURE 23.ANTIDEPRESSANT DRUGS MARKET FOR SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY COUNTRY, 2020-2030 ($MILLION); FIGURE 24.ANTIDEPRESSANT DRUGS MARKET FOR SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, BY COUNTRY, 2020-2030 ($MILLION); FIGURE 25.ANTIDEPRESSANT DRUGS MARKET FOR MONOAMINE OXIDASE INHIBITORS, BY COUNTRY, 2020-2030 ($MILLION); FIGURE 26.ANTIDEPRESSANT DRUGS MARKET FOR SEROTONIN ANTAGONIST AND REUPTAKE INHIBITORS, BY COUNTRY, 2020-2030 ($MILLION); FIGURE 27.ANTIDEPRESSANT DRUGS MARKET FOR OTHERS, BY COUNTRY, 2020-2030 ($MILLION); FIGURE 28.ANTIDEPRESSANT DRUGS MARKET FOR TRICYCLIC ANTIDEPRESSANTS, BY COUNTRY, 2020-2030 ($MILLION); FIGURE 29.ALKERMES PLC: NET SALES, 2018-2020 ($MILLION); FIGURE 30.ALKERMES PLC: REVENUE SHARE, BY SEGMENT, 2020 (%); FIGURE 31.ALKERMES PLC: REVENUE SHARE, BY REGION, 2020 (%); FIGURE 32.ABBVIE INC.: NET SALES, 2018-2020 ($MILLION); FIGURE 33.ABBVIE INC.: REVENUE SHARE, BY SEGMENT, 2020 (%); FIGURE 34.ABBVIE INC.: REVENUE SHARE, BY REGION, 2020 (%); FIGURE 35.ELI LILLY AND COMPANY: NET SALES, 2018-2020 ($MILLION); FIGURE 36.ELI LILLY AND COMPANY: REVENUE SHARE, BY SEGMENT, 2020 (%); FIGURE 37.ELI LILLY AND COMPANY: REVENUE SHARE, BY REGION, 2020 (%); FIGURE 38.GLAXOSMITHKLINE, INC: NET SALES, 2018-2020 ($MILLION); FIGURE 39.GLAXOSMITHKLINE, INC: REVENUE SHARE, BY SEGMENT, 2020 (%); FIGURE 40.GLAXOSMITHKLINE, INC: REVENUE SHARE, BY REGION, 2020 (%); FIGURE 41.H. LUNDBECK A S: NET SALES, 2018-2020 ($MILLION); FIGURE 42.H. LUNDBECK A S: REVENUE SHARE, BY SEGMENT, 2020 (%); FIGURE 43.H. LUNDBECK A S: REVENUE SHARE, BY REGION, 2020 (%); FIGURE 44.F. HOFFMANN-LA ROCHE LTD: NET SALES, 2018-2020 ($MILLION); FIGURE 45.F. HOFFMANN-LA ROCHE LTD: REVENUE SHARE, BY SEGMENT, 2020 (%); FIGURE 46.F. HOFFMANN-LA ROCHE LTD: REVENUE SHARE, BY REGION, 2020 (%); FIGURE 47.MERCK KGAA: NET SALES, 2018-2020 ($MILLION); FIGURE 48.MERCK KGAA: REVENUE SHARE, BY SEGMENT, 2020 (%); FIGURE 49.MERCK KGAA: REVENUE SHARE, BY REGION, 2020 (%); FIGURE 50.PFIZER INC: NET SALES, 2018-2020 ($MILLION); FIGURE 51.PFIZER INC: REVENUE SHARE, BY SEGMENT, 2020 (%); FIGURE 52.PFIZER INC: REVENUE SHARE, BY REGION, 2020 (%); FIGURE 53.TEVA PHARMACEUTICAL INDUSTRIES LTD: NET SALES, 2018-2020 ($MILLION); FIGURE 54.TEVA PHARMACEUTICAL INDUSTRIES LTD: REVENUE SHARE, BY SEGMENT, 2020 (%); FIGURE 55.TEVA PHARMACEUTICAL INDUSTRIES LTD: REVENUE SHARE, BY REGION, 2020 (%); FIGURE 56.TAKEDA PHARMACEUTICAL LIMITED COMPANY: NET SALES, 2018-2020 ($MILLION); FIGURE 57.TAKEDA PHARMACEUTICAL LIMITED COMPANY: REVENUE SHARE, BY SEGMENT, 2020 (%); FIGURE 58.TAKEDA PHARMACEUTICAL LIMITED COMPANY: REVENUE SHARE, BY REGION, 2020 (%)